Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Fortress Biotech Inc

FBIO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$2.93

▼ -1.68%

Market Cap $97.72M · Vol 274.09K

Key Metrics

P/E Ratio

0.92

FWD: 3.29

Market Cap

$97.72M

Micro Cap

Div Yield

N/A

EPS Growth

+2,257.14%

YoY

RSI (14)

39.51

Momentum

Beta

1.19

vs Market

52W High

$4.53

35.32% below

52W Low

$1.98

47.98% above

Volume

274.09K

Avg 170.40K

P/B

2.30

Price-to-book

ROE

N/A

Return on equity

Free Float

76.00%

Public shares

Shariah Compliance8 STANDARDS

✗ Fortress Biotech Inc (FBIO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FBIO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.74%

-21.45%

+27.39%

-18.84%

YTD

-19.95%

+49.49%

-61.97%

-93.66%

Financials & Valuation

TTM · Annual

Total Revenue	$63.26M
Net Income	$-32,915,000.00
Revenue Growth (YoY)	+22.06%
Gross Margin	60.19%
Operating Margin	-111.00%
Net Profit Margin	-52.03%
ROE	N/A
ROA · ROIC	-20.34% · N/A

P/E Ratio	0.92
Forward P/E (FY1)	3.29
PEG Ratio	N/A
P/S	1.61
P/B	2.30
P/FCF	N/A
EPS Growth	+2,257.14%
Outstanding Shares	33.35M

Technical Indicators

50-Day SMA	$3.06
200-Day SMA	$2.99
RSI (14)	39.51
Beta	1.19
52-Week High	$4.53
52-Week Low	$1.98

Volume Today	274.09K
Avg Daily Volume (30D)	170.40K
Relative Volume	1.61x
Volatility (10D)	87.64
Volatility (30D)	77.89
Free Float	76.00%

Analyst Consensus

BUY

Current Price $2.93

Mean Target $11.00

52W Low$1.98 52W High$4.53

Current

Target

$1.98 $4.53

Current Analyst target

+275.43% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GB64

ISINUS34960Q3074

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13R?2 CAR T Cell Program for Glioblastoma), and others.